Zoryl MV 2 Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, thereby reducing insulin resistance. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, leading to a reduction in postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Zoryl MV 2 is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy. It should be used under medical supervision with regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia and gastrointestinal disturbances. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological defects.